F.D.A. Panel Declines to Endorse Alzheimer’s Drug – The New York Times
The drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. But the advisory panel said there was not enough evidence of its effectiveness in slowing cognitive decline. Click Here to Read the...
Read more